Immunodeficiency Virus (e.g., Hiv, Etc.) Patents (Class 424/208.1)
  • Patent number: 8603490
    Abstract: The invention provides methods and compositions for raising an immune response in a subject by administering an HIV antigen. The HIV antigens include HIV clade C polynucleotides and polypeptides. The invention also provides for recombinant HIV viral particles and compositions.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: December 10, 2013
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventor: Ruth M. Ruprecht
  • Publication number: 20130316326
    Abstract: The present invention relates to the use of a Severe Combined T-B-Immune Deficient (SCID) mouse engrafted with human immunocompetent cells (Hu-SCID-mouse) as an animal model for the evaluation of the effectiveness of an HIV vaccine. Furthermore, the present invention relates to a method for the evaluation of an HIV vaccine, wherein a Hu-SCID-mouse of the invention is inoculated with the HIV vaccine and thereafter challenged with HI-virus. The invention also relates to novel HIV vaccine compositions, which can be evaluated using the animal model.
    Type: Application
    Filed: June 3, 2011
    Publication date: November 28, 2013
    Applicant: TECHNOLOGIE INTEGRALE LTD.
    Inventor: Elena Yu Filinova
  • Patent number: 8586056
    Abstract: The present application relates to a novel HIV-1 envelope glycoprotein which may be utilized as an HIV-1 vaccine immunogen, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: November 19, 2013
    Assignee: International AIDS Vaccine Initiative
    Inventors: Sanjay K. Phogat, Wayne C. Koff, Charles Richter King, Denise Wagner, Simon Hoffenberg
  • Patent number: 8586052
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: November 19, 2013
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 8586055
    Abstract: This invention provides DNA vaccines for the treatment of patients undergoing anti-retroviral therapy. The vaccines are surprisingly effective at controlling viremia.
    Type: Grant
    Filed: January 14, 2008
    Date of Patent: November 19, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Barbara Felber, George N. Pavlakis
  • Publication number: 20130302364
    Abstract: The invention relates to peptides comprising part or all of a conserved element within a Center-of-Tree (COT) sequence derived from a family of polypeptides encoded by naturally occurring variants of HIV. The invention also relates to immunogenic compositions and vaccines comprising said peptides. The invention also relates to methods for the identification of HIV controller patients based on the detection of the T cells of the patient to mount a cytotoxic T cell response against said peptides and to methods for the identification of immunogenic peptides within a family of variant polypeptides.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 14, 2013
    Applicants: LABORATORIOS DEL DR. ESTEVE, S.A., UNIVERSITY OF WASHINGTON, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, FUNDACIÓ PRIVADA INSTITUT DE RECERCA DE LA SIDA - CAIXA
    Inventors: Beatriz Mothe Pujadas, Christian Brander, James I. Mullins
  • Patent number: 8580492
    Abstract: The present invention provides isolated methylated Tat peptides; and compositions comprising the peptides. The present invention further provides isolated antibodies specific for a Lys-51-methylated Tat polypeptide. Also provided are methods of identifying agents that inhibit Lys-51 methylation of a Tat polypeptide. The present invention further provides methods of treating an immunodeficiency virus infection in a mammalian subject.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: November 12, 2013
    Assignee: The J. David Gladstone Institutes
    Inventors: Melanie Ott, Sara Pagans Lista
  • Patent number: 8574590
    Abstract: The present invention relates to lipoparticles. The invention also relates to producing lipoparticles. The invention further relates to lipoparticles comprising a viral structural protein. The invention further relates to a lipoparticle comprising a membrane protein, and the lipoparticle can be attached to a sensor surface. The invention further relates to methods of producing and using the lipoparticle to, inter alia, assess protein binding interactions.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: November 5, 2013
    Assignee: Integral Molecular, Inc.
    Inventors: Benjamin J. Doranz, Sharon Willis, Eric Ross, Tiffani Anne Greene
  • Patent number: 8568734
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: October 29, 2013
    Assignee: Novartis Vaccines and Diagnostics Inc.
    Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W Barnett, Indresh K. Srivastava, Rino Rappuoli
  • Patent number: 8563693
    Abstract: The invention includes a heparin activated Antithrombin III encapsulated into a sterically stabilized anti-HLA-DR immunoliposome for the treatment of HIV infection in a human patient.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: October 22, 2013
    Assignee: Acceleration Biopharmaceuticals, Inc.
    Inventor: Ralf Geiben-Lynn
  • Publication number: 20130273103
    Abstract: The present invention relates, in general, to HIV-1 and, in particular, to polyvalent immunogens suitable for use in inducing an immune response to HIV-1 in a patient, and to methods of identifying such immunogens. The invention further relates to methods of inducing an anti-HIV-1 immune response using such immunogens.
    Type: Application
    Filed: September 28, 2011
    Publication date: October 17, 2013
    Applicants: LOS ALAMOS NATIONAL SECURITY, LLC, DUKE UNIVERSITY
    Inventors: Hua-xin Liao, Alan S. Lapedes, Barton F. Haynes, Bette T. Korber
  • Publication number: 20130273101
    Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 17, 2011
    Publication date: October 17, 2013
    Applicant: EYEGENE, INC.
    Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won Il Yoo
  • Patent number: 8557533
    Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: October 15, 2013
    Inventors: Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
  • Publication number: 20130266611
    Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Application
    Filed: March 10, 2013
    Publication date: October 10, 2013
    Applicant: International AIDS Vaccine Initiative
    Inventors: Svetlana Rabinovich, Maoli Yuan, Aaron J. Wilson, Sanjay Phogat, Ross W. B. Lindsay, Maria J. Chiuchiolo, Christopher L. Parks
  • Patent number: 8551483
    Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: October 8, 2013
    Assignees: Innate Pharma S.A.S., Novo Nordisk A/S
    Inventors: Peter Andreas Nicolai Reumert Wagtmann, Francois Romagne, Joakim Glamann
  • Patent number: 8551497
    Abstract: The present invention includes cold-adapted, acid-fast bacterium for use as a vaccine and a vaccine vector. In preferred embodiments, the cold-adapted, acid-fast bacterium is a Mycobacteria, for example, Mycobacteria shottsii.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: October 8, 2013
    Assignee: University of Georgia Research Foundations, Inc.
    Inventors: Frederick Quinn, Candace McCombs, Russell K. Karls
  • Publication number: 20130243850
    Abstract: The present invention relates, in general, to human immunodeficiency vims (HIV-1) and, in particular, to a method of enhancing an immune response to an HIV-1 immunogen, and to compounds and compositions suitable for use in such a method.
    Type: Application
    Filed: November 23, 2011
    Publication date: September 19, 2013
    Applicant: DUKE UNIVERSITY
    Inventors: Barton F. Haynes, Laurent Verkoczy, Anthony M. Moody, Matt T. Holl, Masayuki Kuraoka, Garnett Kelsoe
  • Patent number: 8535684
    Abstract: A method for identifying host genes and encoded proteins for potential targets for therapeutic intervention employs a Gene Search Vector that is either lentivirus or MMLV-based, and can be used to interrogate an entire cell genome without prior knowledge of the genomic sequence. This Random Homozygous Gene Perturbation (RUGP) technique is rapidly verifiable and is used to identify potential host targets for intervention for influenza, HIV and other viral infections. Using Thermal Assymetric Interlaced (TAIL)-PCR, the period for identification of promising targets is reduced from months to weeks or less. Specific targets including PTCH1, Robo1 and Nedd4 are reviewed in detail.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: September 17, 2013
    Assignee: Functional Genetics, Inc.
    Inventors: Michael S. Kinch, Michael Goldblatt, Wu-Bo Li, Douty Bamba, Shaojing Chang, Huosheng Chen, Zenbework Fesseha, Manu Kohli, Hanwen Mao, Heather Thi Thu Ung-Medoff, Ke Weng
  • Patent number: 8501193
    Abstract: The invention relates to a vaccine composition comprising at least one type of anti-HIV vaccine composition containing at least one type of stabilized Tat antigen and to the use thereof for preventing and/or treating a human HIV infection.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: August 6, 2013
    Assignee: Commissariat a l'Energie Atomique
    Inventors: Pascal Drevet, Evelyne Lajeunesse, Alain Lecoq, Michel Leonetti, André Menez, Gervaise Moine, Robert Thai
  • Publication number: 20130183339
    Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150,
    Type: Application
    Filed: March 6, 2013
    Publication date: July 18, 2013
    Applicant: Intercell AG
    Inventor: Intercell AG
  • Patent number: 8486420
    Abstract: The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an immune response by administration of the same to a subject.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: July 16, 2013
    Assignees: The University of North Carolina at Chapel Hill, Children's Hospital, Inc.
    Inventors: Robert E. Johnston, Philip R. Johnson, Christy K. Jurgens, Kelly Young Poe
  • Publication number: 20130171192
    Abstract: A pharmaceutical composition including an adjuvant effective amount of a protected inosine monophosphate (IMP) compound. The pharmaceutical composition includes the protected IMP compound alone, or in combination with vaccine agents with or without additional adjuvants. The pharmaceutical composition can be utilized as a vaccine composition or can be included with existing vaccine compositions in order to increase a specific T lymphocyte mediated immune response thereto. Various methods relating to the pharmaceutical composition and the vaccine are described herein. The vaccines can be employed to prevent or treat infections. Additionally, the pharmaceutical compositions not only increase T-cell responses, but also confer, by pretreatment, non-specific protection against a variety of pathogens. This combination of actions is appropriate for enhancing defense against bioterrorism with organisms like smallpox and anthrax.
    Type: Application
    Filed: October 23, 2012
    Publication date: July 4, 2013
    Applicant: IRX Therapeutics, Inc.
    Inventor: IRX Therapeutics, Inc.
  • Patent number: 8475799
    Abstract: The invention relates to isolated monoclonal antibodies which specifically bind to the C-terminal heptad repeat region of gp41 (HR2) and neutralize an HIV-1 primary isolate.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: July 2, 2013
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventor: Abraham Pinter
  • Publication number: 20130164328
    Abstract: This disclosure demonstrates a novel therapy immunological approach using polyamine-based therapy (PBT) for relieving tumor-induced suppression of the patient's immune system. The demonstration of the pharmacological release from the naturally occurring polyamine-mediated immune suppression offers profound impact on the immunotherapy of cancer together with a variety of diseases caused by the disease-causing vector's ability to evade an immune reaction. This therapeutic approach is equally applicable to disease states whereby immune system suppression by polyamines has been demonstrated including; bacterial infections, parasitic infections including malaria and typanosomiasis, viral infections, peptic ulcers and gastric cancer due to H. Pylori infection together with prevention of pregnancy. With a small molecule drug, used in combination with DFMO, the pharmacological manipulation of polyamine levels for therapeutic benefit in various disease states is possible.
    Type: Application
    Filed: February 20, 2013
    Publication date: June 27, 2013
    Applicants: Lankenau Institute For Medical Research, Aminex Therapeutics
    Inventors: Aminex Therapeutics, Lankenau Institute For Medical Research
  • Patent number: 8470527
    Abstract: The claimed invention is directed toward modified HIV-1 gp41 C-terminal heptad repeat fusion inhibitors. In particular, peptide derivatives of C-34 were prepared (e.g., FB006M) and modified with 3-maleimidoproionic acid (MPA), which allows rapid and irreversible conjugation to serum albumin at a 1:1 molar ratio. These polypeptides have an extended half-life in vivo and display potent antiviral activity against HIV-1.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: June 25, 2013
    Assignee: Frontier Biotechnologies, Co., Ltd.
    Inventors: Dong Xie, He Jiang
  • Patent number: 8470334
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Methods of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: June 25, 2013
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W. Barnett, Indresh K. Srivastava
  • Publication number: 20130149376
    Abstract: The current invention relates to the field of Biotechnology applied to human health. Here it is described a vaccine vehicle wherein toxins from eukaryotic organisms are encapsulated into multilamellar vesicles obtained by the dehydration-rehydration procedure whose lipidic composition is dipalmitoylphosphatidylcholine:cholesterol in a 1:1 molar ratio for subcutaneous or intramuscular administration. These compositions do not require the use of other adjuvants. The disclosed compositions allow modulation of CTL-specific immune response against one or several antigens co-encapsulated into toxin-containing liposomes. The vaccinal vehicle of the present invention shows advantages over others disclosed by the previous art due to the robustness and functionality of the induced immune response as well as its immunomodulating properties.
    Type: Application
    Filed: July 5, 2011
    Publication date: June 13, 2013
    Applicant: CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Maria Eliana Lanio Ruiz, Luis Enrique Fernández Molina, Rady Judith Laboroe Quintana, Yoelys Cruz Leal, Maria del Carmen Luzardo Lorenzo, Circe Mesa Pardillo, Carlos Manuel Alvarez Valcàrcel, Isabel Fabiola Pazos Santos, Mayra Tejuca Martínez, Aisel Valle Garay, María Eugenia Alonso Biosca, Liem Canet Santos
  • Patent number: 8460678
    Abstract: The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: June 11, 2013
    Assignees: Institut Pasteur, Institut National de la Santéde la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Véronique Zennou, Hüseyin Firat
  • Patent number: 8454972
    Abstract: The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: June 4, 2013
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, GenVec, Inc.
    Inventors: Gary J. Nabel, Ling Xu, Bimal Chakrabarti, Lan Wu, Zhi-yong Yang, Jason G. D. Gall, C. Richter King, Zengguang Wang
  • Patent number: 8450056
    Abstract: A sensor chip for detecting an immune response against a virus, the sensor chip including a substrate having a surface and a plurality of virus-like particles or capsid fragments bound to discrete locations on the surface of the substrate. Detection devices containing the sensor chip and methods of detecting anti-viral immune responses are also described herein.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: May 28, 2013
    Assignee: University of Rochester
    Inventors: Benjamin L. Miller, Tim R. Mosmann, Robert C. Rose, Charles R. Mace
  • Publication number: 20130129747
    Abstract: The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising administering a first unique pathogen antigen to the subject; and administering a second unique pathogen antigen 3-52 weeks after a); wherein the second unique pathogen antigen and the first unique pathogen antigen are immunologically distinct but share conserved sites that are not normally immunogenic for antibodies. Also disclosed herein are assays for detecting cross-protective antibodies, methods of generating novel cross-protective antibodies. Further provided are novel antibodies against influenza.
    Type: Application
    Filed: July 22, 2011
    Publication date: May 23, 2013
    Inventor: John W. Schrader
  • Publication number: 20130115244
    Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.
    Type: Application
    Filed: October 1, 2012
    Publication date: May 9, 2013
    Applicant: Yisheng Biopharma (Singapore) PTE. LTD.
    Inventor: Yisheng Biopharma (Singapore) PTE. LTD.
  • Patent number: 8435543
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: May 7, 2013
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer
  • Publication number: 20130101622
    Abstract: The invention provides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent(s).
    Type: Application
    Filed: May 7, 2012
    Publication date: April 25, 2013
    Applicant: Novartis AG
    Inventors: James SUTTON, Feng Xu, Nicholas Valiante, Jiong Lan
  • Patent number: 8420104
    Abstract: The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or, for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors are either integrative or non-integrative (NI) vectors, dependently upon the purpose of their use. The invention relates to the use of gene transfer vectors for unique or for multiple in vivo administration into a host in need thereof. The field of application of the present application concerns in particular animal treatment or treatment of human being (e.g. prophylactic or therapeutic or symptomatic or curative treatment), gene therapy or vaccination in vivo.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: April 16, 2013
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique, Theravectys
    Inventors: Pierre Charneau, Anne-Sophie Beignon, Frederic Philippe Coutant, Karine Courbeyrette
  • Patent number: 8414900
    Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: April 9, 2013
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer
  • Publication number: 20130078276
    Abstract: The disclosure provides vectors encoding one or more HIV antigens and GM-CSF. Also provided are methods of inducing an immune response in a subject, methods of treating a subject having HIV, and methods of manufacturing a medicament for inducing an immune response that require the use of these vectors and vaccine inserts.
    Type: Application
    Filed: February 18, 2011
    Publication date: March 28, 2013
    Inventors: Harriet L. Robinson, Rama R. Amara, Michael Hellerstein, Lilin Lai
  • Publication number: 20130071424
    Abstract: The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 21, 2013
    Applicant: NEW YORK UNIVERSITY
    Inventors: Timothy CARDOZO, Xiangpeng KONG, Susan ZOLLA-PAZNER
  • Patent number: 8394581
    Abstract: Since FIV-vaccinated cats produce antibodies against FIV, distinguishing them from FIV-infected cats is difficult by serological diagnostic methods using FIV and FIV-derived substances. The present invention enables tests for determining the presence or absence of a FIV vaccination history in a cat by detecting antibodies that are produced as a result of vaccination of a cat with an FIV vaccine, but not as a result of FIV infection. Using the methods of the present invention, whether an anti-FIV antibody-positive cat is infected with FIV or has been vaccinated can be conveniently distinguished.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: March 12, 2013
    Assignee: The Kitasato Institute
    Inventors: Tsutomu Hohdatsu, Kenji Motokawa, Hajime Kusuhara
  • Publication number: 20130058973
    Abstract: Native Tat, when administered to patients with HIV infection, or who are otherwise immunocompromised, is capable of restoring immune functions so as to recognise recall antigens, and to inhibit replication and key signs of HIV disease and other persistent infections and/or their progression.
    Type: Application
    Filed: March 21, 2011
    Publication date: March 7, 2013
    Applicant: VAXXIT SRL
    Inventor: Barbara Ensoli
  • Patent number: 8389275
    Abstract: The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: March 5, 2013
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer, Eva Felder
  • Publication number: 20130052220
    Abstract: Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a yeast vehicle and an antigen that is not complexed to the yeast vehicle is disclosed.
    Type: Application
    Filed: June 12, 2012
    Publication date: February 28, 2013
    Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, GLOBEIMMUNE, INC.
    Inventors: Richard C. Duke, Donald Bellgrau, Alex Franzusoff, Cara C. Wilson
  • Publication number: 20130052221
    Abstract: This invention provides a method of co-delivery of combination DNA and protein immunogenic compositions to enhance protective or therapeutic effects.
    Type: Application
    Filed: February 25, 2011
    Publication date: February 28, 2013
    Applicant: The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services
    Inventors: Barbara K. Felber, George N. Pavlakis
  • Publication number: 20130045180
    Abstract: Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.
    Type: Application
    Filed: January 27, 2012
    Publication date: February 21, 2013
    Inventors: David B. Weiner, Jong J. Kim, Jeong-Im Sin
  • Publication number: 20130045229
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: April 20, 2011
    Publication date: February 21, 2013
    Applicant: KINETA, INC.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Publication number: 20130039944
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: April 20, 2011
    Publication date: February 14, 2013
    Applicant: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Publication number: 20130039945
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: April 20, 2011
    Publication date: February 14, 2013
    Applicant: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Patent number: 8367315
    Abstract: Azido-diarylpyrimidine (azido-DAPY) compounds, and compositions containing such compounds, are provided. In addition, methods of using azido-diarylpyrimidines to inactivate reverse transcriptases, prepare inactivated viruses, and treat or prevent viral infections are also provided.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: February 5, 2013
    Inventor: Adan Rios
  • Patent number: 8367068
    Abstract: A method to induce an immune response in a host in need thereof, comprises administering to the host, recombinant lentiviral vector particles comprising: a) a GAG polypeptide or a functional GAG-polypeptide derivative; b) a POL polypeptide or a functional POL-polypeptide derivative ; c) an ENV polypeptide or a functional ENV-polypeptide derivative; and d) a recombinant polynucleotide. The recombinant polynucleotide comprises a transgene placed under the control of regulatory signals for transcription and expression, regulatory signals, of lentiviral origin, for reverse transcription, expression and packaging, and a polynucleotide comprising a cis-acting central initiation region (cPPT) and a cis-acting termination region (CTS). The regions are of lentiviral origin and are inserted in a functional orientation with the regulatory signals of lentiviral origin. The polynucleotide forms a DNA triplex during reverse transcription.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: February 5, 2013
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Véronique Zennou, Hüseyin Firat
  • Patent number: 8367061
    Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: February 5, 2013
    Assignee: Pomona Ricera S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi